<code id='030D67FD80'></code><style id='030D67FD80'></style>
    • <acronym id='030D67FD80'></acronym>
      <center id='030D67FD80'><center id='030D67FD80'><tfoot id='030D67FD80'></tfoot></center><abbr id='030D67FD80'><dir id='030D67FD80'><tfoot id='030D67FD80'></tfoot><noframes id='030D67FD80'>

    • <optgroup id='030D67FD80'><strike id='030D67FD80'><sup id='030D67FD80'></sup></strike><code id='030D67FD80'></code></optgroup>
        1. <b id='030D67FD80'><label id='030D67FD80'><select id='030D67FD80'><dt id='030D67FD80'><span id='030D67FD80'></span></dt></select></label></b><u id='030D67FD80'></u>
          <i id='030D67FD80'><strike id='030D67FD80'><tt id='030D67FD80'><pre id='030D67FD80'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          Wikipedia

          author:explore    - browse:87
          Bristol Myers Squibb sign
          Courtesy Bristol Myers Squibb

          Bristol Myers Squibb will pay $4.1 billion for RayzeBio, the companies said Tuesday, buying into the fast-growing field of using targeted doses of radiation to treat cancer.

          RayzeBio, which raised about $350 million in a September initial public offering, is working in radiopharmaceuticals, which pair the tumor-killing power of radiation with the precision of targeted cancer therapies. The company is currently running a pivotal trial of its most advanced drug, RYZ101, in neuroendocrine cancer and has a pipeline of treatments for kidney, liver, and other cancers.

          advertisement

          Bristol Myers will pay $62.50 in cash per share of RayzeBio, a roughly 115% premium to the company’s recent trading and more than triple the company’s IPO price.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus